Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

NCT02551991 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: nal-IRI
DRUG: 5 fluorouracil
DRUG: Leucovorin
DRUG: Oxaliplatin

Sponsor

Ipsen